Cancer Generics Market Outlook 2017
The National Cancer Institute has stated that almost half of the population born today will be diagnosed with cancer at some point during their lifetime. With global cancer incidence rising to almost 13 Million in 2012 and majority of blockbuster cancer drugs losing their patent protection, the market for cancer generics is bound to experience prodigious growth.
According to our latest research report “Cancer Generics Market Outlook 2017”, this market for cancer generics is expected to grow at 13%, reaching US$ 19 Billion by 2017. The low pricing of cancer generics and increased life expectancy will be the major contributors in this growth.
The report provides an insight to the various parameters associated with Cancer Generics. It focuses on the trends and drivers instrumental in shaping the market, evaluating the role of each driver in detail and predicting its possible impact. Also covered is the segmentation of the generics market by disease types, with emphasis on current and future incidence, regional analysis and the patent expiration status of key cancer drugs.
After an exhaustive study, we have segmented the generics market by the various oral and injectable options, encompassing all the recently approved generics along with existing ones. The detailed study of each drug comprises of price analysis of the branded and generic drug, miscellaneous manufacturers of each generic drug, and drug applicability. Also included are the recent developments of generic players in terms of FDA clearances, mergers and acquisitions that have helped them emerge as the key manufacturers.
The thorough study asserts that Cancer Generics is going to be the focus area for majority of players, with the market witnessing entry of a whole range of generics thereby labeling Cancer Generics as a field with enormous growth potential in the near future.
According to our latest research report “Cancer Generics Market Outlook 2017”, this market for cancer generics is expected to grow at 13%, reaching US$ 19 Billion by 2017. The low pricing of cancer generics and increased life expectancy will be the major contributors in this growth.
The report provides an insight to the various parameters associated with Cancer Generics. It focuses on the trends and drivers instrumental in shaping the market, evaluating the role of each driver in detail and predicting its possible impact. Also covered is the segmentation of the generics market by disease types, with emphasis on current and future incidence, regional analysis and the patent expiration status of key cancer drugs.
After an exhaustive study, we have segmented the generics market by the various oral and injectable options, encompassing all the recently approved generics along with existing ones. The detailed study of each drug comprises of price analysis of the branded and generic drug, miscellaneous manufacturers of each generic drug, and drug applicability. Also included are the recent developments of generic players in terms of FDA clearances, mergers and acquisitions that have helped them emerge as the key manufacturers.
The thorough study asserts that Cancer Generics is going to be the focus area for majority of players, with the market witnessing entry of a whole range of generics thereby labeling Cancer Generics as a field with enormous growth potential in the near future.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. CANCER INCIDENCES - CURRENT AND FUTURE PROJECTION
4. CANCER MARKET OUTLOOK: CURRENT AND FUTURE
4.1 Cancer Generics: Market Size
5. MARKET DRIVERS AND TRENDS
5.1 Indian Generics Getting Marketing Approval in US
5.2 Increasing Cancer Prevalence: Driving Generics Market
5.3 Strategic Activity and Alliances on the Rise
5.4 Patent Expiration Continue to Boost Generics Market
5.5 Companies Thriving for New Cancer Generics
6. CANCER GENERICS: MARKET SEGMENTATION BY DISEASE TYPE
6.1 Lung Cancer
6.1.1 Current and Future Incidence
6.1.2 Regional Analysis
6.1.3 Commercialized Drugs: Branded and Generics
6.2 Breast Cancer
6.2.1 Current and Future Incidence
6.2.2 Regional Analysis
6.2.3 Commercialized Drugs: Branded and Generics
6.3 Colorectal Cancer
6.3.1 Current and Future Incidence
6.3.2 Regional Analysis
6.3.3 Commercialized Drugs: Branded and Generics
6.4 Stomach Cancer
6.4.1 Current and Future Incidence
6.4.2 Regional Analysis
6.4.3 Commercialized Drugs: Branded and Generics
6.5 Prostate Cancer
6.5.1 Current and Future Incidence
6.5.2 Regional Analysis
6.5.3 Commercialized Drugs: Branded and Generics
7. CANCER GENERIC DRUGS: MARKET SEGMENTATION BY ORAL AND INJECTABLES
7.1 Oral Generic Drugs
7.1.1 Arimidex (Anastrozole)
7.1.2 Casodex (Bicalutamide)
7.1.3 Aromasin (Exemestane)
7.1.4 Femara (Letrozole)
7.1.5 Megace (Megestrol Acetate)
7.1.6 Purinethol (Mercaptopurine)
7.1.7 Tarceva (Erlotinib)
7.1.8 Nolvadex (Tamoxifen Citrate)
7.1.9 Eulexin (Flutamide)
7.1.10 Hydrea (Hydroxyurea)
7.2 Generic Injectables
7.2.1 Camptosar (Irinotecan Hydrochloride)
7.2.2 Velcade (Bortezomib)
7.2.3 Taxotere (Docetaxel)
7.2.4 Gemzar (Gemcitabine Hydrochloride)
7.2.5 Doxil (Liposomal)
7.2.6 Ifex (Ifosfamide)
8. KEY PLAYERS
8.1 Actavis Inc.
8.2 Mylan
8.3 Roxane Laboratories
8.4 Accord Healthcare
8.5 Sun Pharmaceuticals
8.6 Teva
8.7 Fresnius Kabi
2. RESEARCH METHODOLOGY
3. CANCER INCIDENCES - CURRENT AND FUTURE PROJECTION
4. CANCER MARKET OUTLOOK: CURRENT AND FUTURE
4.1 Cancer Generics: Market Size
5. MARKET DRIVERS AND TRENDS
5.1 Indian Generics Getting Marketing Approval in US
5.2 Increasing Cancer Prevalence: Driving Generics Market
5.3 Strategic Activity and Alliances on the Rise
5.4 Patent Expiration Continue to Boost Generics Market
5.5 Companies Thriving for New Cancer Generics
6. CANCER GENERICS: MARKET SEGMENTATION BY DISEASE TYPE
6.1 Lung Cancer
6.1.1 Current and Future Incidence
6.1.2 Regional Analysis
6.1.3 Commercialized Drugs: Branded and Generics
6.2 Breast Cancer
6.2.1 Current and Future Incidence
6.2.2 Regional Analysis
6.2.3 Commercialized Drugs: Branded and Generics
6.3 Colorectal Cancer
6.3.1 Current and Future Incidence
6.3.2 Regional Analysis
6.3.3 Commercialized Drugs: Branded and Generics
6.4 Stomach Cancer
6.4.1 Current and Future Incidence
6.4.2 Regional Analysis
6.4.3 Commercialized Drugs: Branded and Generics
6.5 Prostate Cancer
6.5.1 Current and Future Incidence
6.5.2 Regional Analysis
6.5.3 Commercialized Drugs: Branded and Generics
7. CANCER GENERIC DRUGS: MARKET SEGMENTATION BY ORAL AND INJECTABLES
7.1 Oral Generic Drugs
7.1.1 Arimidex (Anastrozole)
7.1.2 Casodex (Bicalutamide)
7.1.3 Aromasin (Exemestane)
7.1.4 Femara (Letrozole)
7.1.5 Megace (Megestrol Acetate)
7.1.6 Purinethol (Mercaptopurine)
7.1.7 Tarceva (Erlotinib)
7.1.8 Nolvadex (Tamoxifen Citrate)
7.1.9 Eulexin (Flutamide)
7.1.10 Hydrea (Hydroxyurea)
7.2 Generic Injectables
7.2.1 Camptosar (Irinotecan Hydrochloride)
7.2.2 Velcade (Bortezomib)
7.2.3 Taxotere (Docetaxel)
7.2.4 Gemzar (Gemcitabine Hydrochloride)
7.2.5 Doxil (Liposomal)
7.2.6 Ifex (Ifosfamide)
8. KEY PLAYERS
8.1 Actavis Inc.
8.2 Mylan
8.3 Roxane Laboratories
8.4 Accord Healthcare
8.5 Sun Pharmaceuticals
8.6 Teva
8.7 Fresnius Kabi
LIST OF FIGURES:
Figure 3-1: Global - Number of New Cancer Cases (Million), 2012 & 2020
Figure 4-1: Global - Cancer Drugs Market (Billion US$), 2012-2017
Figure 4-2: Global - Cancer Drugs Market by Drug Class (%), 2013
Figure 4-3: Global - Cancer Generics Market (Billion US$), 2012-2017
Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2009 & 2020
Figure 6-2: Global - New Lung Cancer Cases by Region (%), 2009
Figure 6-3: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
Figure 6-4: Global - Number of New Breast Cancer Cases (Million), 2009 & 2020
Figure 6-5: Global - New Breast Cancer Cases by Region (%), 2009
Figure 6-6: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
Figure 6-7: Global - Number of New Colorectal Cancer Cases (Million), 2009 & 2020
Figure 6-8: Global - New Colorectal Cancer Cases by Region (%), 2009
Figure 6-9: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
Figure 6-10: Global - Number of New Stomach Cancer Cases (Million), 2009 & 2020
Figure 6-11: Global - New Stomach Cancer Cases by Region (%), 2009
Figure 6-12: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
Figure 6-13: Global - Number of New Prostate Cancer Cases (Million), 2009 & 2020
Figure 6-14: Global - New Prostate Cancer Cases by Region (%), 2009
Figure 6-15: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020
Figure 3-1: Global - Number of New Cancer Cases (Million), 2012 & 2020
Figure 4-1: Global - Cancer Drugs Market (Billion US$), 2012-2017
Figure 4-2: Global - Cancer Drugs Market by Drug Class (%), 2013
Figure 4-3: Global - Cancer Generics Market (Billion US$), 2012-2017
Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2009 & 2020
Figure 6-2: Global - New Lung Cancer Cases by Region (%), 2009
Figure 6-3: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
Figure 6-4: Global - Number of New Breast Cancer Cases (Million), 2009 & 2020
Figure 6-5: Global - New Breast Cancer Cases by Region (%), 2009
Figure 6-6: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
Figure 6-7: Global - Number of New Colorectal Cancer Cases (Million), 2009 & 2020
Figure 6-8: Global - New Colorectal Cancer Cases by Region (%), 2009
Figure 6-9: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
Figure 6-10: Global - Number of New Stomach Cancer Cases (Million), 2009 & 2020
Figure 6-11: Global - New Stomach Cancer Cases by Region (%), 2009
Figure 6-12: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
Figure 6-13: Global - Number of New Prostate Cancer Cases (Million), 2009 & 2020
Figure 6-14: Global - New Prostate Cancer Cases by Region (%), 2009
Figure 6-15: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020
LIST OF TABLES:
Table 3-1: Global - New Cases of Top Five Cancer’s by Geography (Number), 2009
Table 3-2: Global - Forecast for New Cases of Top Five Cancer’s by Geography (Number), 2020
Table 5-1: Oncology Drug Master Filings by Market Players
Table 6-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 6-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 6-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 6-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 6-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 7-1: List of Companies Dealing in Generic Arimidex (Anastrozole)
Table 7-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 7-3: List of Companies Dealing in Generic Casodex (Bicalutamide)
Table 7-4: Cost Comparison of Generics and Branded Casodex (Bicalutamide)
Table 7-5: Cost Comparison of Generics and Branded Aromasin (Exemestane)
Table 7-6: List of Companies Dealing in Generic Femara (Letrozole)
Table 7-7: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 7-8: List of Companies Dealing in Generic Megace (Megestrol Acetate)
Table 7-9: Cost Comparison of Generics and Branded Megace (Megestrol Acetate)
Table 7-10: List of Companies Dealing in Generic Purinethol (Mercaptopurine)
Table 7-11 Cost Comparison of Generics and Branded Purinethol (Mercaptopurine)
Table 7-12 Cost Comparison of Generics and Branded Tarceva (Erlotinib)
Table 7-13: List of Companies Dealing in Generic Nolvadex (Tamoxifen Citrate)
Table 7-14 Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
Table 7-15: List of Companies Dealing in Generic Eulexin (Flutamide)
Table 7-16 Cost Comparison of Generics and Branded Eulexin (Flutamide)
Table 7-17: List of Companies Dealing in Generic Hydrea (Hydroxyurea)
Table 7-18: Cost Comparison of Generics and Branded Hydrea (Hydroxyurea)
Table 7-19: List of Companies Dealing in Generic Camptosar (Irinotecan Hydrochloride)
Table 7-20: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 7-21: Cost Comparison of Generics and Branded Velcade (bortezomib)
Table 7-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 7-23 Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 7-24: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 7-25: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 7-26: Cost Comparison of Generics and Branded Doxil (Doxorubicin Hydrochloride)
Table 7-27: List of Companies Dealing in Generic Ifex (Ifosfamide)
Table 8-1: Actavis - Key Cancer Generic Drugs
Table 8-2: Mylan - Key Cancer Generic Drugs
Table 8-3: Roxane - Key Cancer Generic Drugs
Table 8-4: Accord Healthcare - Key Cancer Generic Drugs
Table 8-5: Sun Pharmaceuticals - Key Cancer Generic Drugs
Table 8-6: Teva Pharmaceuticals - Key Cancer Generic Drugs
Table 8-7: Fresnius Kabi Pharmaceuticals - Key Cancer Generic Drugs
Table 3-1: Global - New Cases of Top Five Cancer’s by Geography (Number), 2009
Table 3-2: Global - Forecast for New Cases of Top Five Cancer’s by Geography (Number), 2020
Table 5-1: Oncology Drug Master Filings by Market Players
Table 6-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 6-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 6-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 6-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 6-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 7-1: List of Companies Dealing in Generic Arimidex (Anastrozole)
Table 7-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 7-3: List of Companies Dealing in Generic Casodex (Bicalutamide)
Table 7-4: Cost Comparison of Generics and Branded Casodex (Bicalutamide)
Table 7-5: Cost Comparison of Generics and Branded Aromasin (Exemestane)
Table 7-6: List of Companies Dealing in Generic Femara (Letrozole)
Table 7-7: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 7-8: List of Companies Dealing in Generic Megace (Megestrol Acetate)
Table 7-9: Cost Comparison of Generics and Branded Megace (Megestrol Acetate)
Table 7-10: List of Companies Dealing in Generic Purinethol (Mercaptopurine)
Table 7-11 Cost Comparison of Generics and Branded Purinethol (Mercaptopurine)
Table 7-12 Cost Comparison of Generics and Branded Tarceva (Erlotinib)
Table 7-13: List of Companies Dealing in Generic Nolvadex (Tamoxifen Citrate)
Table 7-14 Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
Table 7-15: List of Companies Dealing in Generic Eulexin (Flutamide)
Table 7-16 Cost Comparison of Generics and Branded Eulexin (Flutamide)
Table 7-17: List of Companies Dealing in Generic Hydrea (Hydroxyurea)
Table 7-18: Cost Comparison of Generics and Branded Hydrea (Hydroxyurea)
Table 7-19: List of Companies Dealing in Generic Camptosar (Irinotecan Hydrochloride)
Table 7-20: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 7-21: Cost Comparison of Generics and Branded Velcade (bortezomib)
Table 7-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 7-23 Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 7-24: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 7-25: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 7-26: Cost Comparison of Generics and Branded Doxil (Doxorubicin Hydrochloride)
Table 7-27: List of Companies Dealing in Generic Ifex (Ifosfamide)
Table 8-1: Actavis - Key Cancer Generic Drugs
Table 8-2: Mylan - Key Cancer Generic Drugs
Table 8-3: Roxane - Key Cancer Generic Drugs
Table 8-4: Accord Healthcare - Key Cancer Generic Drugs
Table 8-5: Sun Pharmaceuticals - Key Cancer Generic Drugs
Table 8-6: Teva Pharmaceuticals - Key Cancer Generic Drugs
Table 8-7: Fresnius Kabi Pharmaceuticals - Key Cancer Generic Drugs
